AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18272934 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein meal (43% protein, 30% carbohydrate)
Number of subjects: 20
Study 18272934 — intervention group
Group type: COMPARATOR
Intervention: Prior exercise (Ex+D)
Number of subjects: 20
Study 16817279 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Pinellia Decoction for Draining the Heart
Number of subjects: 78
Study 16817279 — intervention group
Group type: COMPARATOR
Intervention: Jinsang Liyan Wan (Pills for a Good Voice by Relieving Sore‐Throat)
Number of subjects: 78
Study 14510744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral esomeprazole (40 mg o.d.)
Number of subjects: 30
Study 14510744 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pantoprazole (40 mg o.d.)
Number of subjects: 30
Study 10981843 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive suppression during film viewing
Number of subjects: 0
Study 10981843 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive suppression during slide viewing
Number of subjects: 0
Study 10981843 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical expressive suppression
Number of subjects: 0
Study 10981843 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 0
Study 9213835 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 30
Study 9213835 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 30
Study 1316307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy plus subcutaneous interferon (IFN) alpha 2a
Number of subjects: 30
Study 1316307 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 30
Study 3927805 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam orally
Number of subjects: 10
Study 3927805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31357949 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Home‐bAsed Reablement Program (I‐HARP)
Number of subjects: 176
Study 31357949 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐HARP
Number of subjects: 176
Study 29316236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin (tofo-tofo group)
Number of subjects: 210
Study 29316236 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Tofogliflozin (pla-tofo group)
Number of subjects: 210
Study 26707354 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg/kg)
Number of subjects: 41
Study 26707354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24460905 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention for children in troubled families
Number of subjects: 116
Study 24460905 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (care as usual)
Number of subjects: 116
Study 22488557 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg) administered intravenously during endoscopy (GL group)
Number of subjects: 30
Study 22488557 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine butylbromide (10 mg) administered intravenously during endoscopy (SC group)
Number of subjects: 30
Study 22488557 — intervention group
Group type: COMPARATOR
Intervention: No medications used prior to PET (NO group)
Number of subjects: 30
Study 19757017 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% UC781 gel
Number of subjects: 36
Study 19757017 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% UC781 gel
Number of subjects: 36
Study 19757017 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study 17391324 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5*1/*1 or *1/*3 genotype
Number of subjects: 29
Study 17391324 — intervention group
Group type: COMPARATOR
Intervention: CYP3A5*3/*3 genotype
Number of subjects: 29
Study 17391324 — intervention group
Group type: COMPARATOR
Intervention: MDR1 diplotypes (CGC‐CGC, CGC‐TTT, CGC‐TGC, TTT‐TGC, TTT‐TTT)
Number of subjects: 29
Study 14966345 — intervention group
Group type: EXPERIMENTAL
Intervention: IVCA-cryo
Number of subjects: 50
Study 14966345 — intervention group
Group type: COMPARATOR
Intervention: IVCA
Number of subjects: 50
Study 11602495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4453
Study 11602495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4453
Study 9639377 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing (10 minutes)
Number of subjects: 70
Study 9639377 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil infusion
Number of subjects: 70
Study 9639377 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antiarrhythmic drugs (procainamide, propafenone, propranolol, dl-sotalol, amiodarone)
Number of subjects: 70
Study 9639377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing-induced AF
Number of subjects: 70
Study 9639377 — intervention group
Group type: EXPERIMENTAL
Intervention: All antiarrhythmic drugs
Number of subjects: 70
Study 7990854 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) at a mean dose of 37 +/- 10 mg intramuscularly
Number of subjects: 9
Study 7990854 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) co-administered with a mildly dyskinetic dose of levodopa infused intravenously
Number of subjects: 9
Study 7990854 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) at low doses (2.5 and 5 mg)
Number of subjects: 9
Study 2732639 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy with lactose formula
Number of subjects: 25
Study 2732639 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy with non-lactose formula
Number of subjects: 25
Study 31958428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 8838
Study 31958428 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent to bisphosphonate therapy
Number of subjects: 8838
Study 31958428 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant users of vitamin D and calcium and a bisphosphonate
Number of subjects: 8838
Study 31958428 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 1 fracture on different dates during the study period
Number of subjects: 8838
Study 31958428 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwent DXA testing prior to bisphosphonate prescription and incident fracture
Number of subjects: 8838
Study 29555258 — intervention group
Group type: EXPERIMENTAL
Intervention: mXELIRI with or without bevacizumab
Number of subjects: 650
Study 29555258 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI with or without bevacizumab
Number of subjects: 650
Study 28778994 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel prehabilitation protocol (10-day bundle of interventions: physiotherapy, nutritional supplementation, cognitive training)
Number of subjects: 62
Study 28778994 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 62
Study 26632301 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received a video demonstration and participated in a discussion and analysis of the control group's videotaped performance.
Number of subjects: 60
Study 26632301 — intervention group
Group type: COMPARATOR
Intervention: Control group received a video demonstration of the exercise.
Number of subjects: 60
Study 24283172 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol hemihydrate 2 mg
Number of subjects: 52
Study 24283172 — intervention group
Group type: COMPARATOR
Intervention: No menopausal therapy (Control)
Number of subjects: 52
Study 20864469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave signal at 385.25 MHz
Number of subjects: 120
Study 20864469 — intervention group
Group type: COMPARATOR
Intervention: 16 Hz pulsing signal
Number of subjects: 120
Study 20864469 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 120
Study 18462083 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete genotypic susceptibility score (dGSS)
Number of subjects: 234
Study 18462083 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous genotypic susceptibility score (cGSS)
Number of subjects: 234
Study 18462083 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic susceptibility scores (GSS)
Number of subjects: 234
Study 18462083 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease mutations at codons 24 and 90
Number of subjects: 234
Study 18462083 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations at codon 82
Number of subjects: 234
Study 18462083 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-associated mutations (K103N)
Number of subjects: 234
Study 16574815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bibliotherapy
Number of subjects: 23
Study 16574815 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive psychotherapy
Number of subjects: 23
Study 16574815 — intervention group
Group type: COMPARATOR
Intervention: Cognitive bibliotherapy and Individual cognitive psychotherapy
Number of subjects: 23
Study 12814333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg/day
Number of subjects: 1079
Study 12814333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1079
Study 15877555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological intervention (5 consecutive days and nights of efforts to decrease daytime in-bed time, 30 minutes or more of daily sunlight exposure, increased physical activity, structured bedtime routine, and efforts to decrease nighttime noise and light)
Number of subjects: 118
Study 15877555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological intervention
Number of subjects: 118
Study 15877555 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 118
Study 10328256 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (50 to 60 mg/kg per day)
Number of subjects: 70
Study 10328256 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (15 to 20 mg/kg per day)
Number of subjects: 70
Study 8960948 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutamine
Number of subjects: 45
Study 8960948 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 45
Study 8960948 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutamine and Exercise
Number of subjects: 45
Study 2022014 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 324 mg daily
Number of subjects: 231
Study 2022014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 6807469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alpha-blockade and beta-blockade with labetalol
Number of subjects: 12
Study 6807469 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockade with propranolol
Number of subjects: 12
Study 28689679 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 110
Study 25496464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 1 mg BID
Number of subjects: 317
Study 25496464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 3 mg BID
Number of subjects: 317
Study 25496464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 317
Study 25496464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 317
Study 25496464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg BID
Number of subjects: 317
Study 25496464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 25234524 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 100
Study 25234524 — intervention group
Group type: COMPARATOR
Intervention: Bur removal (traditional technique)
Number of subjects: 100
Study 22549298 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy training modules (three 60-minute sessions)
Number of subjects: 99
Study 22549298 — intervention group
Group type: COMPARATOR
Intervention: Standard post-graduate medical education
Number of subjects: 99
Study 19631946 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based regimens
Number of subjects: 9193
Study 17322494 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 60 microg/kg daily
Number of subjects: 406
Study 17322494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 17322494 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) (15, 30 microg/kg daily)
Number of subjects: 406
Study 17322494 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 406
Study 15460882 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental tracking optical coherence tomography (OCT) system
Number of subjects: 0
Study 15460882 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite OCT images averaged over multiple scans and visits
Number of subjects: 0
Study 11245709 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg three times daily)
Number of subjects: 10
Study 11245709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9716583 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (5 microgram/kg/d) subcutaneously
Number of subjects: 198
Study 9716583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 9716583 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 198
Study 8037160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive thromboplastin (ISI, 1.3)
Number of subjects: 84
Study 8037160 — intervention group
Group type: COMPARATOR
Intervention: Standard thromboplastin (ISI, 1.9)
Number of subjects: 84
Study 3230200 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 30
Study 3230200 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 30482460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TCh)
Number of subjects: 125
Study 30482460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 125
Study 30482460 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural Control (CP) exercises
Number of subjects: 125
Study 29283609 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping for Health Inventory‐Couples Version (HHI‐C)
Number of subjects: 268
Study 26503137 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liquid nutrition supplement (ONS) intervention
Number of subjects: 154
Study 26503137 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack intervention
Number of subjects: 154
Study 26503137 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 154
Study 26503137 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study 26503137 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS intervention
Number of subjects: 154
Study 23351730 — intervention group
Group type: EXPERIMENTAL
Intervention: Long leg cast immobilization until postoperative week 5, followed by a 0° locking brace until week 12.
Number of subjects: 44
Study 23351730 — intervention group
Group type: COMPARATOR
Intervention: 0° locking brace until postoperative week 12 without cast immobilization.
Number of subjects: 44
Study 21249386 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged strenuous exercise (60 min at 75% effort)
Number of subjects: 10
Study 19917874 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 395
Study 19917874 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 395
Study 19917874 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Hydrochlorothiazide and Atenolol)
Number of subjects: 395
Study 19917874 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide strategy
Number of subjects: 395
Study 19917874 — intervention group
Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 395
Study 19917874 — intervention group
Group type: COMPARATOR
Intervention: Uric acid
Number of subjects: 395
Study 17416123 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior glide mobilization
Number of subjects: 20
Study 17416123 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior glide mobilization
Number of subjects: 20
Study 15815207 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status (full-time and part-time)
Number of subjects: 225
Study 15815207 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (Inflammatory Bowel Disease Questionnaire, Short Form-36)
Number of subjects: 225
Study 15815207 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with unemployment
Number of subjects: 225
Study 15815207 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with receiving disability compensation
Number of subjects: 225
Study 15815207 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status of unemployed patients
Number of subjects: 225
Study 12039398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy, 40-60 sessions of oxygen breathing at 2.5-bar increased pressure in a hyperbaric chamber
Number of subjects: 38
Study 12039398 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 38
Study 12039398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 38
Study 10607254 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose, short-duration interferon-alpha2b (10 million units for 14 weeks)
Number of subjects: 58
Study 10607254 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon regimen (3 MU three times weekly for 6 months)
Number of subjects: 58
Study 10607254 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose, short-duration interferon-alpha2b
Number of subjects: 58
Study 10607254 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon regimen
Number of subjects: 58
Study 8607618 — intervention group
Group type: COMPARATOR
Intervention: CAF + TAM therapy (Arm A)
Number of subjects: 114
Study 8607618 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + MPA therapy (Arm B)
Number of subjects: 114
Study 2182234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anistreplase (APSAC)
Number of subjects: 0
Study 2182234 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 0
Study 2182234 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 6933004 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 24
Study 6933004 — intervention group
Group type: COMPARATOR
Intervention: No BCG immunotherapy
Number of subjects: 24
Study 30545701 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0μg·kg‐1 i.v.)
Number of subjects: 160
Study 30545701 — intervention group
Group type: COMPARATOR
Intervention: Labetalol (0.3 mg·kg‐1 i.v.)
Number of subjects: 160
Study 28964366 — intervention group
Group type: EXPERIMENTAL
Intervention: 500mL of a functional beverage enriched with 200mL of grape pomace (GP)
Number of subjects: 12
Study 28964366 — intervention group
Group type: COMPARATOR
Intervention: 500mL of a control beverage without grape pomace (GP)
Number of subjects: 12
Study 25682576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (15 or 20 mg twice a day)
Number of subjects: 309
Study 25682576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 23832291 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis (PH)
Number of subjects: 101
Study 23832291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 101
Study 23832291 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD)
Number of subjects: 101
Study 21791454 — intervention group
Group type: EXPERIMENTAL
Intervention: hylan G-F 20 (Synvisc)
Number of subjects: 151
Study 21791454 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 151
Study 19351941 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus aerobic exercise training (36 supervised sessions followed by home-based training)
Number of subjects: 2331
Study 19351941 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus aerobic exercise training
Number of subjects: 2331
Study 19351941 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2331
Study 16776357 — intervention group
Group type: EXPERIMENTAL
Intervention: X STOP IPD device
Number of subjects: 75
Study 16776357 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 75
Study 15005950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 0
Study 15005950 — intervention group
Group type: COMPARATOR
Intervention: Diet and lifestyle advice
Number of subjects: 0
Study 11706929 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer decision support software
Number of subjects: 447
Study 11706929 — intervention group
Group type: COMPARATOR
Intervention: Control (no software)
Number of subjects: 447
Study 9415336 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg ondansetron suppository once a day
Number of subjects: 420
Study 9415336 — intervention group
Group type: COMPARATOR
Intervention: 8 mg intravenous ondansetron on day 1 followed by 8 mg tablet twice daily on days 2 and 3 (i.v. + p.o. group)
Number of subjects: 420
Study 8424510 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine (20 mL of 1.37% lidocaine plus 1 mL sodium bicarbonate per 10 mL 1.5% lidocaine)
Number of subjects: 26
Study 8424510 — intervention group
Group type: COMPARATOR
Intervention: Non-alkalinized lidocaine (20 mL of 1.37% lidocaine with added 1:200,000 epinephrine)
Number of subjects: 26
Study 3310622 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscrotal testosterone system
Number of subjects: 3
Study 3310622 — intervention group
Group type: COMPARATOR
Intervention: 200 mg of testosterone enanthate
Number of subjects: 3
Study 29016466 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based teaching method
Number of subjects: 30
Study 29016466 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 30